A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC)

Category Primary study
JournalJournal of Clinical Oncology
Year 2014
This article has no abstract
Epistemonikos ID: 53e7611be1b5199f04e504e5ccd226f44dbea6ac
First added on: Feb 06, 2025